90686

Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use

CPT code 90686 represents a quadrivalent inactivated influenza vaccine (IIV4) that is formulated as a split virus, preservative-free preparation for intramuscular injection. This vaccine is designed to provide active immunization against four distinct strains of the influenza virus: two influenza A subtypes (typically H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). The 'quadrivalent' designation signifies a broader spectrum of protection compared to older trivalent vaccines, which only included one B-strain lineage. The 'split virus' nomenclature indicates that the influenza virus has been chemically disrupted or 'split' by detergents to reduce the likelihood of systemic reactions while maintaining high immunogenicity. This specific code specifies a 0.5 mL dosage, which is the standard volume for patients three years of age and older, and in some brand formulations, for children as young as six months. Being preservative-free (often lacking thimerosal), this formulation is frequently selected for pediatric populations, pregnant women, or individuals with known sensitivities to vaccine preservatives. Clinically, 90686 represents the vaccine product itself. The procedure involves pre-vaccination screening for contraindications like Guillain-Barre syndrome or severe egg allergies, clinical assessment of the patient's current health status, and the physical preparation of the syringe. It is important to note that while 90686 describes the biological product, the provider must also report a separate administration code (such as 90460 or 90471) to reflect the clinical labor, supplies, and risk associated with the injection process. Documentation must include the vaccine manufacturer, lot number, expiration date, and the specific site of the intramuscular injection to meet medical necessity and compliance standards.

Clinical Indications

  • Annual seasonal influenza prophylaxis for individuals aged 3 years and older (and infants 6-35 months where FDA approved for 0.5mL dose).
  • Prevention of influenza-related complications in high-risk populations, including those with chronic pulmonary, cardiovascular, or metabolic disorders.
  • Immunization of healthcare workers to prevent nosocomial transmission of influenza.
  • Prophylaxis for household contacts and caregivers of persons at high risk for influenza complications.
  • Active immunization for pregnant women during any trimester of pregnancy during flu season.

Procedure Steps

  1. Verify patient identity and perform a clinical review for allergies (specifically egg protein or vaccine components) and history of Guillain-Barre syndrome.
  2. Provide the patient or guardian with the most current Influenza Vaccine Information Statement (VIS) and answer questions.
  3. Perform a visual inspection of the vaccine for discoloration or particulate matter before administration.
  4. Aseptically prepare the 0.5 mL dose using a single-dose vial or a prefilled syringe.
  5. Identify the appropriate intramuscular injection site (typically the deltoid muscle for adults/children or the anterolateral thigh for younger children).
  6. Cleanse the injection site with an alcohol swab and allow to dry.
  7. Administer the vaccine via intramuscular injection at a 90-degree angle to the skin.
  8. Withdraw the needle and apply gentle pressure or a bandage to the site.
  9. Monitor the patient for at least 15 minutes post-injection for any signs of immediate allergic reactions or syncope.
  10. Document the vaccine name, dose, site, manufacturer, lot number, and expiration date in the medical record.

Coding Guidelines

  • Code 90686 identifies the vaccine product only; always report a separate vaccine administration code (e.g., 90460, 90461, 90471, or 90472).
  • Do not report 90686 if the vaccine administered is trivalent (use 90656-90658) or contains preservatives (use 90688).
  • For pediatric patients (6 months through 35 months) receiving a 0.25 mL dose, use 90685 instead of 90686.
  • If a significant, separately identifiable evaluation and management (E/M) service is performed at the same visit, append modifier 25 to the E/M code.
  • Check specific payer policies for age requirements, as some payers require 90686 for all patients 6 months and older if the 0.5 mL dose is used.
  • Parenthetical instructions in the CPT manual indicate that 90686 is specifically for the 0.5 mL preservative-free intramuscular formulation.

Associated ICD-10 Codes